亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

ANG-2

總結
Angiopoietin-2 predicts the efficacy of angiogenesis inhibitors in colorectal cancer therapy.
技術優勢
Ang-2 level as predictive biomarker for angiognese-targeted therapeutical approaches of CRC.
Low pretherapeutic serum Ang-2 levels are associated with: reduced risk of death, increased progression-free survival.
技術應用
Cancer Therapy- Strong diagnostic potential of the predictive biomarker has been demonstrated in pretherapeutic blood samples from colorectal cancer patients vs. healthy controls
詳細技術說明
A novel predictive biomarker to help identify the patient population with the most favorable clinical outcome to angiogenesis-targeted treatment in mCRC patients.Experiments revealed that patients with low pretherapeutic Ang-2 serum levels receiving a bevacizumab-containing treatment were associated with a better response rate compared to patients with high pretherapeutic Ang-2 levels
合作類型
Licensing
申請日期
06/09/2010 00:00:00
申請號碼
EP20100757580 20100906
分類
- international:
G01N33/68
- cooperative:
G01N33/57419; G01N2333/515; G01N2800/52; G01N2800/56
其他
Patent application
ID號碼
2262
國家/地區
德國

欲了解更多信息,請點擊 這裡
移動設備